- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Ionis Pharmaceuticals is a biotechnology business based in the US. Ionis Pharmaceuticals shares (IONS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $39.71 – an increase of 3.36% over the previous week. Ionis Pharmaceuticals employs 927 staff and has a trailing 12-month revenue of around $813.5 million.
What's in this guide?
Our top picks for where to buy Ionis Pharmaceuticals stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Ionis Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – IONS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Ionis Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Ionis Pharmaceuticals stock price (NASDAQ: IONS)
Use our graph to track the performance of IONS stocks over time.Ionis Pharmaceuticals shares at a glance
Latest market close | $39.71 |
---|---|
52-week range | $35.95 - $54.44 |
50-day moving average | $42.56 |
200-day moving average | $44.25 |
Wall St. target price | $61.72 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-2.52 |
Is it a good time to buy Ionis Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Ionis Pharmaceuticals price performance over time
Historical closes compared with the close of $40.36 from 2024-10-28
1 week (2024-10-22) | 4.34% |
---|---|
1 month (2024-09-30) | 0.75% |
3 months (2024-07-30) | -18.92% |
6 months (2024-04-30) | -2.18% |
1 year (2023-10-30) | -8.27% |
---|---|
2 years (2022-10-26) | -9.00% |
3 years (2021-10-29) | 26.64% |
5 years (2019-10-30) | 56.72 |
Is Ionis Pharmaceuticals stock undervalued or overvalued?
Valuing Ionis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ionis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ionis Pharmaceuticals's PEG ratio
Ionis Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 25.7033. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ionis Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ionis Pharmaceuticals financials
Revenue TTM | $813.5 million |
---|---|
Gross profit TTM | $-257,866,000 |
Return on assets TTM | -7.58% |
Return on equity TTM | -105.71% |
Profit margin | -44.96% |
Book value | $1.81 |
Market Capitalization | $6.1 billion |
TTM: trailing 12 months
Ionis Pharmaceuticals share dividends
We're not expecting Ionis Pharmaceuticals to pay a dividend over the next 12 months.
Ionis Pharmaceuticals share price volatility
Over the last 12 months, Ionis Pharmaceuticals's shares have ranged in value from as little as $35.95 up to $54.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ionis Pharmaceuticals's is 0.384. This would suggest that Ionis Pharmaceuticals's shares are less volatile than average (for this exchange).
Ionis Pharmaceuticals overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
Frequently asked questions
What percentage of Ionis Pharmaceuticals is owned by insiders or institutions?Currently 0.781% of Ionis Pharmaceuticals shares are held by insiders and 98.093% by institutions. How many people work for Ionis Pharmaceuticals?
Latest data suggests 927 work at Ionis Pharmaceuticals. When does the fiscal year end for Ionis Pharmaceuticals?
Ionis Pharmaceuticals's fiscal year ends in December. Where is Ionis Pharmaceuticals based?
Ionis Pharmaceuticals's address is: 2855 Gazelle Court, Carlsbad, CA, United States, 92010 What is Ionis Pharmaceuticals's ISIN number?
Ionis Pharmaceuticals's international securities identification number is: US4622221004 What is Ionis Pharmaceuticals's CUSIP number?
Ionis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 462222100
More guides on Finder
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question